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Young Lives Lost as B Cells Falter: What We Are Learning
About Antibody Responses in Malaria
Silvia Portugal, Susan K. Pierce, and Peter D. Crompton
Plasmodium falciparum malaria remains a major public
health threat for which there is no licensed vaccine. Abs
play a key role in malaria immunity, but Ab-mediated
protection is only acquired after years of repeated infec-
tions, leaving children in endemic areas vulnerable to
severe malaria and death. Many P. falciparum Ags are
extraordinarily diverse and clonally variant, which likely
contribute to the inefficient acquisition of protective
Abs. However, mounting evidence suggests that there
is more to the story and that infection-induced dysreg-
ulation of B cell function also plays a role. We herein
review progress toward understanding the B cell biol-
ogy of P. falciparum infection, focusing on what has
been learned from population-based studies in malaria-
endemic areas. We suggest ways in which advances in
immunology and genomics-based technology can fur-
ther improve our understanding of the B cell response
in malaria and perhaps illuminate new pathways to the
development of effective vaccines. The Journal of Im-
munology, 2013, 190: 3039–3046.
M
alaria is caused by mosquito-borne parasites of the
genus Plasmodium. Of the five Plasmodium species
that infect humans, P. falciparum is the deadliest,
each year causing ∼225 million cases of malaria and nearly
one million deaths, with most being among African children
and pregnant women (http://www.who.int/malaria/world_
malaria_report_2011/en/) (1). Optimism that a first-gen-
eration malaria vaccine, RTS,S, may soon be licensed has been
tempered by the interim results of an ongoing phase 3 clinical
trial in Africa that indicated that the vaccine confers short-lived
protection from malaria in only ∼30% of infants (2). Clearly,
the ongoing effort to develop a highly effective vaccine would
benefit from a more detailed understanding of malaria im-
munity.
P. falciparum has a complex life cycle (Fig. 1) (3–22) in
which only the blood stage of infection is associated with
disease, typically an undifferentiated febrile illness that in a
minority of cases progresses to severe disease and death (23).
Epidemiologic studies in areas where individuals are repeat-
edly infected with P. falciparum show that immunity to se-
vere, life-threatening malaria is usually acquired early in
childhood, whereas immunity to uncomplicated febrile malaria
is not reliably acquired until early adulthood (3), and once
acquired appears to wane (24), at least partially (25), in the
absence of ongoing P. falciparum exposure. Despite decades of
exposure, sterile immunity to infection develops rarely if at all
(3), as adults often carry blood-stage parasites without symp-
toms. In this review we focus our attention on naturally ac-
quired immunity to the blood stage of P. falciparum infection
where B cells are known to play a critical role in protection.
The central role of Abs in naturally acquired malaria im-
munity was shown by early experiments in which the transfer
of purified IgG from malaria-immune West African adults to
children with malaria in West Africa (8), East Africa (26), or
Thailand (27) led to rapid and profound reductions in parasite
numbers in the blood and resolution of fever. More than 50 y
after understanding that Abs mediate malaria immunity, it
remains a major challenge to determine which of the ∼5400
predicted P. falciparum proteins (28) elicit protective Abs and
the mechanisms by which these Abs protect (described in Fig.
1) (29). Indeed, without this information there are currently
no unambiguous immune correlates of protection from
malaria. It also remains incompletely understood why the
acquisition of Ab-mediated immunity is so slow to develop
(30, 31). The gradual acquisition of protective Abs has been
proposed to be due in large part to the extensive genetic di-
versity of many P. falciparum Ags (17) as well as the parasite’s
ability to clonally vary the Ags it expresses on the surface of
infected RBCs (iRBCs) (32). The reasoning goes that it may
take years living in an endemic area for an individual to be
exposed to a sufficient number of parasite clones to generate
protective Abs. However, the data supporting this view are not
ironclad. We herein review studies that point toward an alter-
native but non–mutually exclusive explanation for the gradual
acquisition of Ab immunity to malaria; that is, that P. falciparum
subverts B cell responses, making the acquisition of protective
Abs inefficient, particularly as compared with responses to
other pathogens in which long-lived Ab-mediated protection is
acquired after a single or few exposures.
The Ab response to malaria
How clone-specific are Abs that protect against malaria? The pro-
posal that the slow acquisition of protective Abs in individuals
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FIGURE 1. The P. falciparum life cycle: no shortage of Ab targets. The P. falciparum life cycle in humans includes the asymptomatic liver stage; the blood stage,
which causes disease; and the sexual gametocyte blood stage, which infects mosquitoes that transmit the parasite. Infection begins when Anopheles mosquitoes inject
sporozoites into the skin and blood (a) which migrate to the liver and invade a small number of hepatocytes (b). Each sporozoite gives rise to thousands of asexual
parasites called merozoites (c). About 1 wk after hepatocyte invasion, merozoites exit the liver into the bloodstream and begin a 48-h cycle (d) of RBC invasion,
replication, RBC rupture, and merozoite release (e). Once inside RBCs, the parasite exports variant surface Ags such as PfEMP1 to the RBC surface. Variant surface
Ags mediate binding of iRBCs to the microvascular endothelium of various organs (f) and placental tissue (g), allowing parasites to avoid splenic clearance and
promoting the inflammation and circulatory obstruction associated with clinical syndromes such as cerebral malaria (coma) and pregnancy-associated malaria. Variant
surface Ag–mediated rosetting (binding of iRBCs to RBCs) may also contribute to disease (h). A small number of blood-stage parasites differentiate into sexual
gametocytes (i), which are taken up by mosquitoes ( j) where they differentiate into gametes that fuse to form a motile zygote, the ookinete (k), where meiosis occurs.
The ookinete crosses the midgut wall and forms an oocyst (l) that develops into sporozoites that enter the mosquito salivary gland to complete the life cycle (a). Abs
that sterilely protect by neutralizing sporozoites (a) and/or blocking hepatocyte invasion (b) are rarely if ever acquired through natural infection (3). Abs induced by
the RTS,S vaccine target the circumsporozoite protein on the sporozoite surface (4) and correlate with sterile protection in malaria-naive adults (5); however, in African
children, RTS,S generally protects against disease and not infection, and the correlation between Abs and protection is less clear (6, 7). Abs are a key component of
naturally acquired blood-stage immunity (8), but the Ag targets and mechanisms of protection are incompletely understood and likely multifaceted. Abs may
contribute to protection by clearing merozoites (9) and iRBCs (e) through opsonization (10) or complement-mediated lysis (11), by (Figure legend continues)
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living in malaria-endemic areas is due to the time required to
be exposed to a large number of P. falciparum clones predicts
that Abs to P. falciparum variant Ags should be highly clone
specific. A major target of protective Abs in malaria appears
to be P. falciparum erythrocyte membrane protein 1 (PfEMP1)
expressed on the surface of iRBCs (33). PfEMP1s are encoded
by the highly polymorphic var multigene family (∼60 genes/
genome), and their expression is clonally variant (32). PfEMP1s
mediate adhesion of iRBCs to microvascular endothelium,
allowing the parasite to sequester in capillaries of various organs
and avoid destruction in the spleen (Fig. 1) (23). Additionally,
sequestration of iRBCs in organs such as the brain and placenta
has been linked to the pathogenesis of clinical syndromes such as
cerebral malaria and pregnancy-associated malaria (Fig. 1) (34).
Several studies support the hypothesis that repeated infections are
required to elicit a protective repertoire of PfEMP1-specific Abs
(33, 35–40). However, other studies suggest that there is a
limited subset of common PfEMP1s Ags that are important
targets of immunity (41–44) or that protective Abs target cross-
reactive or conserved epitopes on PfEMP1s (45–50). The
observation that purified IgG from immune West African
adults was therapeutic in children not only in West Africa
but in East Africa (26) and Thailand as well (27) suggests a
significant degree of Ab cross-reactivity to genetically diverse
P. falciparum parasites (51). Taken together these observations
raise the possibility that the gradual acquisition of protective
Abs may not simply be a reflection of the time required for an
individual to be exposed to all the parasite clones circulating
in a given endemic area.
How long-lived is the Ab response to P. falciparum? It is well
established that long-lived protective Ab responses, which are
induced by many pathogens and vaccines after one or a few
exposures (52), depend on the generation of high-affinity
memory B cells (MBCs) and long-lived plasma cells (LLPCs)
(53–55). LLPCs reside in the bone marrow where they
constitutively secrete Abs and provide a critical first line of
defense against reinfection, whereas MBCs mediate recall Ab
responses after re-exposure to their Ag by rapidly proliferating
and differentiating into plasma cells.
Although there is significant heterogeneity in the magnitude,
quality, and longevity of Ab responses following infection or
vaccination, in general, Ab responses are long-lived. For in-
stance, estimates of half-lives of IgG responses range from 11 y
for tetanus vaccines to .300 y for measles vaccines (52, 55).
In sharp contrast, the half-lives of P. falciparum–specific Ab
responses generally appear to be much shorter, particularly in
young children. For example, in a 12-wk study of Kenyan
children following acute malaria, the half-lives of IgG re-
sponses specific for five merozoite surface Ags (56) were
estimated to be 9.8 d for IgG1 and 6.1 d for IgG3. In ad-
ditional longitudinal studies, P. falciparum–specific Ab re-
sponses have been reported to decline to undetectable or
nearly undetectable levels within 3–9 mo of documented
malaria episodes in children (57–65). It is of interest that Ab
responses to conserved (or semiconserved) P. falciparum Ags
(59) or conserved regions of polymorphic Ags (62), to which
individuals presumably were repeatedly exposed, were simi-
larly short-lived. Taken together, these studies in children
indicate that P. falciparum infection does not reliably induce
a stable pool of LLPCs. Short-lived P. falciparum–specific IgG
responses have also been observed in older children and adults
(59, 62, 66). In contrast, there are studies that point toward
more stable IgG responses with increasing age in areas of
stable P. falciparum transmission (57, 61, 63, 67, 68); how-
ever, it is important to note that in such areas it is difficult to
separate the effects of age and cumulative P. falciparum ex-
posure on malaria immunity. Data from transmigrant studies
in Indonesia suggest that adults may acquire clinical immu-
nity to malaria more rapidly than do children (69, 70), but
this bears further investigation as the risk of clinical malaria
was similar among previously unexposed children and adults
during a malaria epidemic in Madagascar (25).
How might these differences in the estimates of the duration
of Ab responses be reconciled? It is possible that studies that
reported short-lived P. falciparum–specific Ab responses were
biased by the small number of Ags examined. Indeed, the
studies cited above measured IgG responses specific for one
or a few Ags, often blood-stage merozoite surface Ags being
developed as vaccine candidates (15) that together represent
,0.5% of the predicted P. falciparum proteome (28). How-
ever, a recent study that employed protein microarray tech-
nology (71) to assess the IgG response to ∼25% of the P.
falciparum proteome, including proteins expressed at all stages
of the parasite life cycle, showed that children exposed to
intense seasonal P. falciparum transmission generate IgG re-
sponses to hundreds of P. falciparum Ags each transmission
season. However, these declined rapidly during the 6-mo dry
season, a period of little to no P. falciparum transmission (Fig.
2). These data suggest a preferential induction of short-lived
plasma cells during P. falciparum infection that is not re-
stricted to a subset of intrinsically less immunogenic proteins.
Even though Ab responses to P. falciparum Ags in children
are short-lived, ultimately by adulthood stable Ab levels are
acquired. The study cited above showed that with each year of
P. falciparum exposure, the level of IgG persisting through
the dry season gradually increased until young adulthood
when IgG levels were maintained at high levels (Fig. 2). One
simple explanation for the gradual buildup of P. falciparum–
specific IgGs with age is the incremental accumulation of
LLPCs with each year of exposure. How important for pro-
tection are long-lived Ab responses? An age-adjusted analysis
in the same study showed that the overall level of P. falciparum–
specific IgG present before but not after the malaria season
predicted protection from malaria (71).
inhibiting merozoite invasion of RBCs (d) (12), and/or by blocking adhesion of iRBCs to vascular endothelium (f) (13). Nonneutralizing Abs may contribute to
protection through Ab-dependent monocyte- (14) or NK cell–mediated cytotoxicity. Blood-stage vaccines have focused primarily on generating Abs to merozoite
proteins but with limited success (15, 16), probably due to Ag polymorphism (16, 17) and redundant RBC invasion pathways (18). Of note, the conserved
merozoite protein PfRh5 appears to be essential for RBC invasion (19) and may be susceptible to vaccine-inducible cross-strain neutralizing Ab (20). Protection
from pregnancy-associated malaria correlates with IgG specific for VAR2CSA, a conserved protein that mediates adherence to placental tissue (g) (21). Vaccine-
induced Abs targeting Ags on gametocytes and gametes that are ingested with the blood meal (i–l) could prevent parasite development in the mosquito and block
or reduce transmission (22).
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Taken together, these data suggest that the gradual acqui-
sition of clinical immunity to malaria may reflect the need for
repeated infections to “fill” the P. falciparum–specific LLPC
compartment to the point where steady-state Ab levels exceed
a protective threshold. Conversely, MBC-mediated Ab boost-
ing in response to acute infection, a process that generally
peaks 6–10 d after Ag re-exposure, may not be rapid enough
to prevent the onset of symptoms, which can occur as early as
3 d after blood-stage infection begins (72). Similar models
have been postulated for other pathogens with short incuba-
tion periods such as Haemophilus influenzae type b (73), in
which the infection progresses to a symptomatic threshold
more rapidly than MBC-mediated Ab boosting, such that
protection depends on already circulating Abs. In this light, it
is likely that an effective blood-stage malaria vaccine will need
to establish a critical level of circulating IgG produced by a
stable pool of LLPCs, rather than depend on MBC-mediated
Ab boosting. This may be especially important in areas of
sporadic P. falciparum transmission where boosting of Ab re-
sponses does not occur through regular natural exposure. The
same principle likely applies to vaccines targeting sporozoites
that are in the bloodstream and exposed to Abs only tran-
siently before invading hepatocytes.
The continued use of high-throughput Ab profiling methods
(74) in various epidemiological settings in conjunction with
systems biology approaches (75) to describe the contribution
of T cells and innate immunity will improve our under-
standing of the factors that influence the specificity, longevity,
and quality of Ab responses to malaria. A more detailed un-
derstanding of the mechanisms that ultimately confer pro-
tection against malaria and the reasons for their inefficient
acquisition could help advance malaria vaccine development.
The MBC response to malaria
It was initially speculated that P. falciparum infection might
not generate MBCs based on anecdotal evidence of waning
malaria immunity in the absence of P. falciparum exposure, as
well as inconsistent Ab boosting upon reinfection (56), even
to conserved Ags (59). However, several recent studies have
now shown that P. falciparum–specific MBCs can indeed be
generated in response to natural infection, albeit inefficiently.
For example, a longitudinal study in Mali, where there is an
annual 6-mo malaria season, found that the frequency of
MBCs specific for two blood-stage Ags, AMA-1 and MSP-1,
increased incrementally with each malaria season, from
childhood to adulthood (60). Moreover, MBCs once acquired
appear to be long-lived. For example, a recent study in Kenya
reported that P. falciparum–specific MBCs were found to
persist longer than Abs in the absence of ongoing P. falcipa-
rum exposure (76). However, the Mali study showed that
despite exposure to ∼60 infective mosquito bites per month
at the peak of the malaria season, only ∼50% of adults had
detectable P. falciparum–specific MBCs (60). A low preva-
lence (∼30–50%) of P. falciparum–specific MBCs has also
been reported in adults in studies conducted in The Gambia
(77), Kenya (78), and Thailand (68), even in individuals with
documented Plasmodium infection within 6 y (68). The
findings for P. falciparum–induced MBCs are in sharp con-
trast to studies that show, for example, that smallpox vaccine–
specific MBCs are generated and persist in nearly all vaccinees
for $50 y in the absence of Ag re-exposure (79). Thus, it
appears that P. falciparum infection can generate long-lived
MBCs but less efficiently, at least compared with vaccines for
other pathogens. Although it might be predicted that the
prevalence and frequencies of P. falciparum–specific MBCs
would be higher in areas of intense versus sporadic P. falcip-
arum transmission, studies to date suggest that this is not the
case (60, 68, 77, 80), raising the possibility that chronic or
persistent P. falciparum exposure may be detrimental to MBC
generation.
What might underlie the inefficient acquisition of P. falciparum–
specific LLPCs and MBCs? Several mechanisms have been pro-
posed to explain the relatively inefficient acquisition of P.
falciparum–specific LLPCs and MBCs (Table I) (81–91). Be-
cause of limited space we comment on only a few possibilities
for which there are recent data.
The relative inefficiency in acquiring P. falciparum–specific
LLPCs and MBCs may be related to dysregulated B cell Ag-
FIGURE 2. The P. falciparum-specific IgG re-
sponse is broad but short-lived in children. Shown
is IgG reactivity (red) specific for 491 P. falciparum
proteins (columns) in plasma collected from chil-
dren (n = 157) and adults (n = 37) before and after
an intense 6-mo malaria season (see Ref. 71 for
detailed methods and results). The average IgG
level for each protein is stratified by 1-y age groups
from 2 to 21 y, and within each age group from
before to after the malaria season (rows). A broad
P. falciparum–specific IgG response is present after
the 6-mo malaria season in children as young as
2 y; however, the IgG response in young children is
short-lived based on IgG levels at the end of the
6-mo dry season, a period of little to no P. falciparum
transmission. With increasing age, IgG levels at the
end of the dry season gradually increase until pla-
teauing in adulthood.
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driven differentiation, particularly in the setting of chronic P.
falciparum exposure. Alterations in B cell function are well
described in the context of chronic infections such as visceral
leishmaniasis (92), HIV (93), and hepatitis C virus (94). For
example, HIV (95) and hepatitis C virus (96) viremia are
associated with an expansion of a subset of B cells identified
by the cell surface markers CD19+CD20+CD212CD272
CD102 and Fc receptor–like-4+ (97). In HIV-infected indi-
viduals, Moir et al. (95) showed that these cells were hypo-
responsive and suggested that these hyporesponsive, or “ex-
hausted” MBCs contribute to the humoral deficiencies observed
in HIV-infected individuals.
Remarkably, an increase in a phenotypically similar subset
of B cells has been observed in P. falciparum–exposed children
and adults (84). In the context of malaria, this B cell subset
has been referred to as “atypical” rather than exhausted be-
cause the function of these B cells and whether they are
beneficial or detrimental in malaria remain unclear. An ex-
pansion of atypical MBCs has also been observed in malaria-
endemic Peru (98), The Gambia (77), Mali (99), Kenya
(100), and Gabon (101), suggesting that P. falciparum–asso-
ciated atypical MBC expansion is generalizable to genetically
and geographically disparate populations, and that the degree
of atypical MBC expansion correlates with P. falciparum
transmission intensity (98). A direct causal relationship be-
tween P. falciparum infection and atypical MBC expansion
remains to be established; however, differential expansion of
atypical MBCs has recently been observed in age-matched
children living under similar conditions in rural Kenya with
the exception of P. falciparum exposure (100), suggesting that
P. falciparum infection per se may drive atypical MBC ex-
pansion. Intriguingly, recent work by Muellenbeck et al.
(101) showed at the single-cell level that P. falciparum ex-
posure is associated with the acquisition of atypical MBCs
that produce broadly neutralizing Abs specific for P. falcipa-
rum blood-stage Ags, and furthermore that atypical MBCs,
unlike classical MBCs, show signs of active Ab secretion, al-
though spontaneous Ab secretion was not noted in other
studies (84, 95). Compared to classical MBCs, atypical MBCs
also differed in their IgG gene repertoire, suggesting that they
develop from different precursors (101).
P. falciparum infections could also dysregulate helper T cell
responses. Interestingly, a recent study showed that PD-1, a
marker of T cell exhaustion, is upregulated on CD4+ T cells
in children following P. falciparum infection (86). Although
the functional significance of this observation in human re-
mains to be determined, Butler et al. (86) reported that
Plasmodium yoelii infection in mice induces phenotypic and
functional CD4+ T cell exhaustion, and that in vivo blockade
of the PD-1 ligand PD-L1 and the inhibitory receptor LAG-3
restored CD4+ T cell function, amplified the number of T
follicular helper and germinal center B cells and plasmablasts,
increased Ab levels, and accelerated the clearance of blood-
stage parasites. To understand the functional link between
putative P. falciparum–specific CD4+ T cell exhaustion and
Ab responses in humans will require tools that allow for the
detection of P. falciparum–specific T cells, including MHC
tetramer technology that has proved to be effective in iden-
tifying pathogen-specific T cells by flow cytometry.
Whether malaria-associated B cell dysregulation is driven by
direct interactions between P. falciparum products and B cells
or indirectly through systemic immune activation is unclear.
To our knowledge the only published example of a direct P.
falciparum/B cell interaction comes from in vitro studies that
implicate the cysteine-rich interdomain regions 1a of PfEMP1
as a T cell–independent polyclonal B cell activator and Ig
binding protein (87). The discovery of direct molecular
interactions between P. falciparum and the human immune
system has been accelerated by systematic protein interaction
screening approaches (102). For example, a yeast two-hybrid
approach identified an interaction between P. falciparum
merozoite surface protein 1 and the proinflammatory protein
S100P (103), and an avidity-based extracellular interaction
screen identified basigin (CD147) as a host receptor essential
for RBC invasion via the merozoite protein PfRh5 (19). In-
triguingly, basigin is also expressed on B and T cells, as well as
dendritic cells, monocytes, and macrophages, raising the pos-
sibility that basigin/PfRh5 interactions may modulate host
responses during P. falciparum infection.
It is also possible that systemic mediators of B cell differ-
entiation and survival (53), such as BAFF, APRIL, IL-4, and
IL-21, are modulated during P. falciparum infection. A recent
study of Kenyan children (89) reported that acute malaria is
associated with elevated plasma levels of BAFF and transient
downregulation of BAFF receptor expression on B cells. In-
terestingly, however, higher levels of BAFF-R expression on
B cells were associated with more durable P. falciparum–
specific IgG responses, suggesting that dysregulated BAFF-R
expression may contribute to inefficient P. falciparum–specific
LLPC responses. It has also been suggested (56) that binding
of iRBCs to bone marrow stromal cells (104) may disrupt PC
survival signals in bone marrow niches.
Chronic exposure to pathogen-associated molecular patterns
could possibly result in tolerance of pattern recognition re-
ceptors expressed on B cells and dendritic cells, which play a
critical role in enhancing B cell responses (105, 106). Al-
though few P. falciparum–derived pathogen-associated mo-
lecular patterns have been identified to date (107–110), recent
clinical trials demonstrate that the TLR9 agonist CpG
markedly enhances the IgG and MBC response to P. falcip-
arum blood-stage vaccine candidates in malaria-naive adults
(111), but not in adults chronically exposed to P. falciparum
in endemic areas (90). Further studies are needed to define
how P. falciparum exposure modulates the function of pattern
recognition receptors and how this might influence homolo-
gous and heterologous LLPC and MBC responses.
Table I. Potential factors contributing to the inefficient acquisition of
P. falciparum-specific protective Abs
Factor Reference
Clonal Ag variation (32)
Ag genetic diversity (17)
Germinal center disruption (81)
Lack of Ab avidity maturation (82)
Marginal zone B cell induction (83)
B cell exhaustion (84)
Increased immature transitional B cells (85)
CD4+ T cell exhaustion (86)




Clonal imprinting/original antigenic sin (OAS) (63)
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It is unclear whether Ab responses in the course of repeated
P. falciparum infections are predominantly derived from
newly recruited naive B cells or cross-reactive MBC clones
generated during prior infections (63) (i.e., clonal imprinting
or OAS). It useful to consider the case of influenza, which
similar to P. falciparum, repeatedly infects much of the world’s
population and exhibits extensive strain diversity. Work by
Wrammert et al. (112) suggests that plasmablasts producing
broadly neutralizing Abs induced by pandemic H1N1 influ-
enza are predominantly derived from activated MBCs specific
for epitopes conserved in several influenza strains, consis-
tent with OAS. Similar analyses of variable gene sequences
from plasmablasts induced by human experimental (72) and
natural P. falciparum infection, particularly serial infections
with genetically distinct P. falciparum parasites, could define
the degree to which OAS operates in malaria and how it relates
to malaria susceptibility.
Conclusions
Although there appears to be more questions than answers as to
how malaria immunity is acquired, it is nonetheless an exciting
time in malaria research. Malaria is one of the few infectious
diseases in which relatively small longitudinal cohort studies of
natural infection are feasible. For example, in areas of intense
seasonal P. falciparum transmission, where nearly all indi-
viduals are predictably exposed to P. falciparum each year, it is
possible to analyze the human immune response before, dur-
ing, and after P. falciparum infection and to prospectively study
immune correlates of protection as well as the immuno-
modulatory effects of infection. Malaria is also one of the
only infectious diseases for which experimental human infec-
tions are approved. These unique study populations coupled
with the powerful tools made available through extraordinary
advances in immunology and systems biology ought to pro-
vide a wealth of information on the impact of P. falciparum
infections on the human immune system and on the acquisi-
tion of malaria immunity.
Disclosures
The authors have no financial conflicts of interest.
References
1. Murray, C. J., L. C. Rosenfeld, S. S. Lim, K. G. Andrews, K. J. Foreman,
D. Haring, N. Fullman, M. Naghavi, R. Lozano, and A. D. Lopez. 2012. Global
malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413–
431.
2. The RTS,S Clinical Trials Partnership. 2012. A phase 3 trial of RTS,S/AS01
malaria vaccine in African infants. N. Engl. J. Med. 367: 2284–2295.
3. Marsh, K., and S. Kinyanjui. 2006. Immune effector mechanisms in malaria.
Parasite Immunol. 28: 51–60.
4. Regules, J. A., J. F. Cummings, and C. F. Ockenhouse. 2011. The RTS,S vaccine
candidate for malaria. Expert Rev. Vaccines 10: 589–599.
5. Kester, K. E., J. F. Cummings, O. Ofori-Anyinam, C. F. Ockenhouse, U. Krzych,
P. Moris, R. Schwenk, R. A. Nielsen, Z. Debebe, E. Pinelis, et al; RTS,S Vaccine
Evaluation Group. 2009. Randomized, double-blind, phase 2a trial of falciparum
malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety,
efficacy, and immunologic associates of protection. J. Infect. Dis. 200: 337–346.
6. Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, J. Milman,
I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, et al. 2004. Efficacy of
the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in
young African children: randomised controlled trial. Lancet 364: 1411–1420.
7. Bejon, P., J. Lusingu, A. Olotu, A. Leach, M. Lievens, J. Vekemans, S. Mshamu,
T. Lang, J. Gould, M. C. Dubois, et al. 2008. Efficacy of RTS,S/AS01E vaccine
against malaria in children 5 to 17 months of age.N. Engl. J. Med. 359: 2521–2532.
8. Cohen, S., I. A. McGREGOR, and S. Carrington. 1961. Gamma-globulin and
acquired immunity to human malaria. Nature 192: 733–737.
9. Fowkes, F. J., J. S. Richards, J. A. Simpson, and J. G. Beeson. 2010. The rela-
tionship between anti-merozoite antibodies and incidence of Plasmodium falcipa-
rum malaria: a systematic review and meta-analysis. PLoS Med. 7: e1000218.
10. Druilhe, P., and S. Khusmith. 1987. Epidemiological correlation between levels
of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and
malaria-immune status. Infect. Immun. 55: 888–891.
11. Stanley, H. A., J. T. Mayes, N. R. Cooper, and R. T. Reese. 1984. Complement
activation by the surface of Plasmodium falciparum infected erythrocytes. Mol.
Immunol. 21: 145–150.
12. Crompton, P. D., K. Miura, B. Traore, K. Kayentao, A. Ongoiba, G. Weiss,
S. Doumbo, D. Doumtabe, Y. Kone, C. Y. Huang, et al. 2010. In vitro growth
inhibitory activity and malaria risk in a cohort study in Mali. Infect. Immun. 78:
737–745.
13. Claessens, A., Y. Adams, A. Ghumra, G. Lindergard, C. C. Buchan, C. Andisi,
P. C. Bull, S. Mok, A. P. Gupta, C. W. Wang, et al. 2012. A subset of group A-
like var genes encodes the malaria parasite ligands for binding to human brain
endothelial cells. Proc. Natl. Acad. Sci. USA 109: E1772–E1781.
14. Bouharoun-Tayoun, H., P. Attanath, A. Sabchareon, T. Chongsuphajaisiddhi, and
P. Druilhe. 1990. Antibodies that protect humans against Plasmodium falciparum
blood stages do not on their own inhibit parasite growth and invasion in vitro, but
act in cooperation with monocytes. J. Exp. Med. 172: 1633–1641.
15. Crompton, P. D., S. K. Pierce, and L. H. Miller. 2010. Advances and challenges in
malaria vaccine development. J. Clin. Invest. 120: 4168–4178.
16. Thera, M. A., O. K. Doumbo, D. Coulibaly, M. B. Laurens, A. Ouattara,
A. K. Kone, A. B. Guindo, K. Traore, I. Traore, B. Kouriba, et al. 2011. A field
trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365: 1004–1013.
17. Takala, S. L., and C. V. Plowe. 2009. Genetic diversity and malaria vaccine design,
testing and efficacy: preventing and overcoming “vaccine resistant malaria”. Par-
asite Immunol. 31: 560–573.
18. Cowman, A. F., and B. S. Crabb. 2006. Invasion of red blood cells by malaria
parasites. Cell 124: 755–766.
19. Crosnier, C., L. Y. Bustamante, S. J. Bartholdson, A. K. Bei, M. Theron,
M. Uchikawa, S. Mboup, O. Ndir, D. P. Kwiatkowski, M. T. Duraisingh, et al.
2011. Basigin is a receptor essential for erythrocyte invasion by Plasmodium fal-
ciparum. Nature 480: 534–537.
20. Douglas, A. D., A. R. Williams, J. J. Illingworth, G. Kamuyu, S. Biswas,
A. L. Goodman, D. H. Wyllie, C. Crosnier, K. Miura, G. J. Wright, et al. 2011.
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-
strain neutralizing antibody. Nat Commun 2: 601.
21. Rogerson, S. J., L. Hviid, P. E. Duffy, R. F. Leke, and D. W. Taylor. 2007.
Malaria in pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7: 105–117.
22. Carter, R. 2001. Transmission blocking malaria vaccines. Vaccine 19: 2309–2314.
23. Miller, L. H., D. I. Baruch, K. Marsh, and O. K. Doumbo. 2002. The pathogenic
basis of malaria. Nature 415: 673–679.
24. Jelinek, T., C. Schulte, R. Behrens, M. P. Grobusch, J. P. Coulaud, Z. Bisoffi,
A. Matteelli, J. Clerinx, M. Coracha´n, S. Puente, et al. 2002. Imported Falciparum
malaria in Europe: sentinel surveillance data from the European network on
surveillance of imported infectious diseases. Clin. Infect. Dis. 34: 572–576.
25. Deloron, P., and C. Chougnet. 1992. Is immunity to malaria really short-lived?
Parasitol. Today 8: 375–378.
26. McGregor, I. A., S. P. Carrington, and S. Cohen. 1963. Treatment of East African
P. falciparum malaria with West African human g-globulin. Trans. R. Soc. Trop.
Med. Hyg. 57: 170–175.
27. Sabchareon, A., T. Burnouf, D. Ouattara, P. Attanath, H. Bouharoun-Tayoun,
P. Chantavanich, C. Foucault, T. Chongsuphajaisiddhi, and P. Druilhe. 1991.
Parasitologic and clinical human response to immunoglobulin administration in
falciparum malaria. Am. J. Trop. Med. Hyg. 45: 297–308.
28. Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman,
J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, et al. 2002. Genome sequence of
the human malaria parasite Plasmodium falciparum. Nature 419: 498–511.
29. Beeson, J. G., F. H. Osier, and C. R. Engwerda. 2008. Recent insights into humoral
and cellular immune responses against malaria. Trends Parasitol. 24: 578–584.
30. Achtman, A. H., P. C. Bull, R. Stephens, and J. Langhorne. 2005. Longevity of the
immune response and memory to blood-stage malaria infection. Curr. Top.
Microbiol. Immunol. 297: 71–102.
31. Struik, S. S., and E. M. Riley. 2004. Does malaria suffer from lack of memory?
Immunol. Rev. 201: 268–290.
32. Scherf, A., J. J. Lopez-Rubio, and L. Riviere. 2008. Antigenic variation in Plas-
modium falciparum. Annu. Rev. Microbiol. 62: 445–470.
33. Chan, J. A., K. B. Howell, L. Reiling, R. Ataide, C. L. Mackintosh, F. J. Fowkes,
M. Petter, J. M. Chesson, C. Langer, G. M. Warimwe, et al. 2012. Targets of
antibodies against Plasmodium falciparum-infected erythrocytes in malaria immu-
nity. J. Clin. Invest. 122: 3227–3238.
34. Beeson, J. G., and G. V. Brown. 2002. Pathogenesis of Plasmodium falciparum
malaria: the roles of parasite adhesion and antigenic variation. Cell. Mol. Life Sci.
59: 258–271.
35. Cham, G. K., L. Turner, J. D. Kurtis, T. Mutabingwa, M. Fried, A. T. Jensen,
T. Lavstsen, L. Hviid, P. E. Duffy, and T. G. Theander. 2010. Hierarchical,
domain type-specific acquisition of antibodies to Plasmodium falciparum erythro-
cyte membrane protein 1 in Tanzanian children. Infect. Immun. 78: 4653–4659.
36. Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and
K. Marsh. 1998. Parasite antigens on the infected red cell surface are targets for
naturally acquired immunity to malaria. Nat. Med. 4: 358–360.
37. Leech, J. H., J. W. Barnwell, L. H. Miller, and R. J. Howard. 1984. Identification
of a strain-specific malarial antigen exposed on the surface of Plasmodium falcip-
arum-infected erythrocytes. J. Exp. Med. 159: 1567–1575.
38. Giha, H. A., T. Staalsoe, D. Dodoo, C. Roper, G. M. Satti, D. E. Arnot, L. Hviid,
and T. G. Theander. 2000. Antibodies to variable Plasmodium falciparum-infected
erythrocyte surface antigens are associated with protection from novel malaria
infections. Immunol. Lett. 71: 117–126.
3044 BRIEF REVIEWS: B CELL RESPONSE TO MALARIA
 at M









39. Marsh, K., L. Otoo, R. J. Hayes, D. C. Carson, and B. M. Greenwood. 1989.
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians
and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg.
83: 293–303.
40. Mackintosh, C. L., T. Mwangi, S. M. Kinyanjui, M. Mosobo, R. Pinches,
T. N. Williams, C. I. Newbold, and K. Marsh. 2008. Failure to respond to the
surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to
clinical malaria amongst African children. Int. J. Parasitol. 38: 1445–1454.
41. Aguiar, J. C., G. R. Albrecht, P. Cegielski, B. M. Greenwood, J. B. Jensen,
G. Lallinger, A. Martinez, I. A. McGregor, J. N. Minjas, J. Neequaye, et al. 1992.
Agglutination of Plasmodium falciparum-infected erythrocytes from east and west
African isolates by human sera from distant geographic regions. Am. J. Trop. Med.
Hyg. 47: 621–632.
42. Bull, P. C., B. S. Lowe, M. Kortok, and K. Marsh. 1999. Antibody recognition of
Plasmodium falciparum erythrocyte surface antigens in Kenya: evidence for rare and
prevalent variants. Infect. Immun. 67: 733–739.
43. Jensen, A. T., P. Magistrado, S. Sharp, L. Joergensen, T. Lavstsen, A. Chiucchiuini,
A. Salanti, L. S. Vestergaard, J. P. Lusingu, R. Hermsen, et al. 2004. Plasmodium
falciparum associated with severe childhood malaria preferentially expresses
PfEMP1 encoded by group A var genes. J. Exp. Med. 199: 1179–1190.
44. Rottmann, M., T. Lavstsen, J. P. Mugasa, M. Kaestli, A. T. Jensen, D. Mu¨ller,
T. Theander, and H. P. Beck. 2006. Differential expression of var gene groups is
associated with morbidity caused by Plasmodium falciparum infection in Tanzanian
children. Infect. Immun. 74: 3904–3911.
45. Marsh, K., and R. J. Howard. 1986. Antigens induced on erythrocytes by P.
falciparum: expression of diverse and conserved determinants. Science 231: 150–
153.
46. Bull, P. C., B. S. Lowe, N. Kaleli, F. Njuga, M. Kortok, A. Ross, F. Ndungu,
R. W. Snow, and K. Marsh. 2002. Plasmodium falciparum infections are associated
with agglutinating antibodies to parasite-infected erythrocyte surface antigens
among healthy Kenyan children. J. Infect. Dis. 185: 1688–1691.
47. Kinyanjui, S. M., T. Mwangi, P. C. Bull, C. I. Newbold, and K. Marsh. 2004.
Protection against clinical malaria by heterologous immunoglobulin G antibodies
against malaria-infected erythrocyte variant surface antigens requires interaction
with asymptomatic infections. J. Infect. Dis. 190: 1527–1533.
48. Ofori, M. F., D. Dodoo, T. Staalsoe, J. A. Kurtzhals, K. Koram, T. G. Theander,
B. D. Akanmori, and L. Hviid. 2002. Malaria-induced acquisition of antibodies to
Plasmodium falciparum variant surface antigens. Infect. Immun. 70: 2982–2988.
49. Giha, H. A., T. Staalsoe, D. Dodoo, I. M. Elhassan, C. Roper, G. M. Satti,
D. E. Arnot, L. Hviid, and T. G. Theander. 1999. Overlapping antigenic reper-
toires of variant antigens expressed on the surface of erythrocytes infected by
Plasmodium falciparum. Parasitology 119: 7–17.
50. Giha, H. A., T. Staalsoe, D. Dodoo, I. M. Elhassan, C. Roper, G. M. Satti,
D. E. Arnot, T. G. Theander, and L. Hviid. 1999. Nine-year longitudinal study of
antibodies to variant antigens on the surface of Plasmodium falciparum-infected
erythrocytes. Infect. Immun. 67: 4092–4098.
51. Manske, M., O. Miotto, S. Campino, S. Auburn, J. Almagro-Garcia, G. Maslen,
J. O’Brien, A. Djimde, O. Doumbo, I. Zongo, et al. 2012. Analysis of Plasmodium
falciparum diversity in natural infections by deep sequencing. Nature 487: 375–
379.
52. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral im-
munity to common viral and vaccine antigens. N. Engl. J. Med. 357: 1903–1915.
53. Goodnow, C. C., C. G. Vinuesa, K. L. Randall, F. Mackay, and R. Brink. 2010.
Control systems and decision making for antibody production. Nat. Immunol. 11:
681–688.
54. Good-Jacobson, K. L., and M. J. Shlomchik. 2010. Plasticity and heterogeneity in
the generation of memory B cells and long-lived plasma cells: the influence of
germinal center interactions and dynamics. J. Immunol. 185: 3117–3125.
55. Amanna, I. J., and M. K. Slifka. 2010. Mechanisms that determine plasma cell
lifespan and the duration of humoral immunity. Immunol. Rev. 236: 125–138.
56. Kinyanjui, S. M., D. J. Conway, D. E. Lanar, and K. Marsh. 2007. IgG antibody
responses to Plasmodium falciparum merozoite antigens in Kenyan children have
a short half-life. Malar. J. 6: 82.
57. Fru¨h, K., O. Doumbo, H. M. Mu¨ller, O. Koita, J. McBride, A. Crisanti, Y. Toure´,
and H. Bujard. 1991. Human antibody response to the major merozoite surface
antigen of Plasmodium falciparum is strain specific and short-lived. Infect. Immun.
59: 1319–1324.
58. Mu¨ller, H. M., K. Fru¨h, A. von Brunn, F. Esposito, S. Lombardi, A. Crisanti, and
H. Bujard. 1989. Development of the human immune response against the major
surface protein (gp190) of Plasmodium falciparum. Infect. Immun. 57: 3765–3769.
59. Fonjungo, P. N., I. M. Elhassan, D. R. Cavanagh, T. G. Theander, L. Hviid,
C. Roper, D. E. Arnot, and J. S. McBride. 1999. A longitudinal study of human
antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a re-
gion of seasonal and unstable malaria transmission. Infect. Immun. 67: 2975–2985.
60. Weiss, G. E., B. Traore, K. Kayentao, A. Ongoiba, S. Doumbo, D. Doumtabe,
Y. Kone, S. Dia, A. Guindo, A. Traore, et al. 2010. The Plasmodium falciparum-
specific human memory B cell compartment expands gradually with repeated
malaria infections. PLoS Pathog. 6: e1000912.
61. Akpogheneta, O. J., N. O. Duah, K. K. Tetteh, S. Dunyo, D. E. Lanar, M. Pinder,
and D. J. Conway. 2008. Duration of naturally acquired antibody responses to
blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect.
Immun. 76: 1748–1755.
62. Cavanagh, D. R., I. M. Elhassan, C. Roper, V. J. Robinson, H. Giha,
A. A. Holder, L. Hviid, T. G. Theander, D. E. Arnot, and J. S. McBride. 1998. A
longitudinal study of type-specific antibody responses to Plasmodium falciparum
merozoite surface protein-1 in an area of unstable malaria in Sudan. J. Immunol.
161: 347–359.
63. Taylor, R. R., A. Egan, D. McGuinness, A. Jepson, R. Adair, C. Drakely, and
E. Riley. 1996. Selective recognition of malaria antigens by human serum anti-
bodies is not genetically determined but demonstrates some features of clonal
imprinting. Int. Immunol. 8: 905–915.
64. Ramasamy, R., K. Nagendran, and M. S. Ramasamy. 1994. Antibodies to epitopes
on merozoite and sporozoite surface antigens as serologic markers of malaria
transmission: studies at a site in the dry zone of Sri Lanka. Am. J. Trop. Med. Hyg.
50: 537–547.
65. John, C. C., J. H. Ouma, P. O. Sumba, M. R. Hollingdale, J. W. Kazura, and
C. L. King. 2002. Lymphocyte proliferation and antibody responses to Plasmo-
dium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal
variation in malaria transmission. Am. J. Trop. Med. Hyg. 66: 372–378.
66. Brown, A. E., H. K. Webster, J. A. Lyon, A. W. Thomas, B. Permpanich, and
M. Gross. 1991. Characterization of naturally acquired antibody responses to
a recombinant fragment from the N-terminus of Plasmodium falciparum glyco-
protein 195. Am. J. Trop. Med. Hyg. 45: 567–573.
67. Riley, E. M., S. Morris-Jones, M. J. Blackman, B. M. Greenwood, and
A. A. Holder. 1993. A longitudinal study of naturally acquired cellular and hu-
moral immune responses to a merozoite surface protein (MSP1) of Plasmodium
falciparum in an area of seasonal malaria transmission. Parasite Immunol. 15: 513–
524.
68. Wipasa, J., C. Suphavilai, L. C. Okell, J. Cook, P. H. Corran, K. Thaikla,
W. Liewsaree, E. M. Riley, and J. C. Hafalla. 2010. Long-lived antibody and B cell
memory responses to the human malaria parasites, Plasmodium falciparum and
Plasmodium vivax. PLoS Pathog. 6: e1000770.
69. Baird, J. K., T. R. Jones, E. W. Danudirgo, B. A. Annis, M. J. Bangs, H. Basri,
Purnomo, and S. Masbar. 1991. Age-dependent acquired protection against
Plasmodium falciparum in people having two years exposure to hyperendemic
malaria. Am. J. Trop. Med. Hyg. 45: 65–76.
70. Baird, J. K., H. Purnomo, H. Basri, M. J. Bangs, E. M. Andersen, T. R. Jones,
S. Masbar, S. Harjosuwarno, B. Subianto, and P. R. Arbani. 1993. Age-specific
prevalence of Plasmodium falciparum among six populations with limited histories
of exposure to endemic malaria. Am. J. Trop. Med. Hyg. 49: 707–719.
71. Crompton, P. D., M. A. Kayala, B. Traore, K. Kayentao, A. Ongoiba, G. E. Weiss,
D. M. Molina, C. R. Burk, M. Waisberg, A. Jasinskas, et al. 2010. A prospective
analysis of the Ab response to Plasmodium falciparum before and after a malaria
season by protein microarray. Proc. Natl. Acad. Sci. USA 107: 6958–6963.
72. Sauerwein, R. W., M. Roestenberg, and V. S. Moorthy. 2011. Experimental hu-
man challenge infections can accelerate clinical malaria vaccine development. Nat.
Rev. Immunol. 11: 57–64.
73. Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect.
Dis. 47: 401–409.
74. Doolan, D. L. 2011. Plasmodium immunomics. Int. J. Parasitol. 41: 3–20.
75. Tran, T. M., B. Samal, E. Kirkness, and P. D. Crompton. 2012. Systems im-
munology of human malaria. Trends Parasitol. 28: 248–257.
76. Ndungu, F. M., A. Olotu, J. Mwacharo, M. Nyonda, J. Apfeld, L. K. Mramba,
G. W. Fegan, P. Bejon, and K. Marsh. 2012. Memory B cells are a more reliable
archive for historical antimalarial responses than plasma antibodies in no-longer
exposed children. Proc. Natl. Acad. Sci. USA 109: 8247–8252.
77. Nogaro, S. I., J. C. Hafalla, B. Walther, E. J. Remarque, K. K. Tetteh,
D. J. Conway, E. M. Riley, and M. Walther. 2011. The breadth, but not the
magnitude, of circulating memory B cell responses to P. falciparum increases with
age/exposure in an area of low transmission. PLoS ONE 6: e25582.
78. Dorfman, J. R., P. Bejon, F. M. Ndungu, J. Langhorne, M. M. Kortok,
B. S. Lowe, T. W. Mwangi, T. N. Williams, and K. Marsh. 2005. B cell memory
to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. J.
Infect. Dis. 191: 1623–1630.
79. Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003.
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J.
Immunol. 171: 4969–4973.
80. Clark, E. H., C. J. Silva, G. E. Weiss, S. Li, C. Padilla, P. D. Crompton,
J. N. Hernandez, and O. H. Branch. 2012. Plasmodium falciparum malaria in the
Peruvian Amazon, a region of low transmission, is associated with immunologic
memory. Infect. Immun. 80: 1583–1592.
81. Urban, B. C., T. T. Hien, N. P. Day, N. H. Phu, R. Roberts, E. Pongponratn,
M. Jones, N. T. Mai, D. Bethell, G. D. Turner, et al. 2005. Fatal Plasmodium
falciparum malaria causes specific patterns of splenic architectural disorganization.
Infect. Immun. 73: 1986–1994.
82. Ibison, F., A. Olotu, D. M. Muema, J. Mwacharo, E. Ohuma, D. Kimani,
K. Marsh, P. Bejon, and F. M. Ndungu. 2012. Lack of avidity maturation of
merozoite antigen-specific antibodies with increasing exposure to Plasmodium
falciparum amongst children and adults exposed to endemic malaria in Kenya.
PLoS ONE 7: e52939.
83. Weill, J. C., S. Weller, and C. A. Reynaud. 2009. Human marginal zone B cells.
Annu. Rev. Immunol. 27: 267–285.
84. Weiss, G. E., P. D. Crompton, S. Li, L. A. Walsh, S. Moir, B. Traore,
K. Kayentao, A. Ongoiba, O. K. Doumbo, and S. K. Pierce. 2009. Atypical
memory B cells are greatly expanded in individuals living in a malaria-endemic
area. J. Immunol. 183: 2176–2182.
85. Asito, A. S., A. M. Moormann, C. Kiprotich, Z. W. Ng’ang’a, R. Ploutz-Snyder,
and R. Rochford. 2008. Alterations on peripheral B cell subsets following an acute
uncomplicated clinical malaria infection in children. Malar. J. 7: 238.
86. Butler, N. S., J. Moebius, L. L. Pewe, B. Traore, O. K. Doumbo, L. T. Tygrett,
T. J. Waldschmidt, P. D. Crompton, and J. T. Harty. 2012. Therapeutic blockade
of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection.
Nat. Immunol. 13: 188–195.
The Journal of Immunology 3045
 at M









87. Donati, D., B. Mok, A. Cheˆne, H. Xu, M. Thangarajh, R. Glas, Q. Chen,
M. Wahlgren, and M. T. Bejarano. 2006. Increased B cell survival and preferential
activation of the memory compartment by a malaria polyclonal B cell activator. J.
Immunol. 177: 3035–3044.
88. Abele, D. C., J. E. Tobie, G. J. Hill, P. G. Contacos, and C. B. Evans. 1965.
Alterations in serum proteins and 19S antibody production during the course of
induced malarial infections in man. Am. J. Trop. Med. Hyg. 14: 191–197.
89. Nduati, E., A. Gwela, H. Karanja, C. Mugyenyi, J. Langhorne, K. Marsh, and
B. C. Urban. 2011. The plasma concentration of the B cell activating factor is
increased in children with acute malaria. J. Infect. Dis. 204: 962–970.
90. Traore, B., Y. Kone´, S. Doumbo, D. Doumtabe´, A. Traore´, P. D. Crompton,
M. Mircetic, C. Y. Huang, K. Kayentao, A. Dicko, et al. 2009. The TLR9 agonist
CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory
B cells in semi-immune adults in Mali. Vaccine 27: 7299–7303.
91. Daniel-Ribeiro, C. T., and G. Zanini. 2000. Autoimmunity and malaria: what are
they doing together? Acta Trop. 76: 205–221.
92. Sakkas, L. I., M. Boulbou, D. Kyriakou, I. Makri, C. Sinani, A. Germenis, and
N. Stathakis. 2008. Immunological features of visceral leishmaniasis may mimic
systemic lupus erythematosus. Clin. Biochem. 41: 65–68.
93. Moir, S., and A. S. Fauci. 2009. B cells in HIV infection and disease. Nat. Rev.
Immunol. 9: 235–245.
94. Sansonno, L., F. A. Tucci, S. Sansonno, G. Lauletta, L. Troiani, and D. Sansonno.
2009. B cells and HCV: an infection model of autoimmunity. Autoimmun. Rev. 9:
93–94.
95. Moir, S., J. Ho, A. Malaspina, W. Wang, A. C. DiPoto, M. A. O’Shea, G. Roby,
S. Kottilil, J. Arthos, M. A. Proschan, et al. 2008. Evidence for HIV-associated
B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected
viremic individuals. J. Exp. Med. 205: 1797–1805.
96. Charles, E. D., R. M. Green, S. Marukian, A. H. Talal, G. V. Lake-Bakaar,
I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2008. Clonal expansion of im-
munoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.
Blood 111: 1344–1356.
97. Ehrhardt, G. R., J. T. Hsu, L. Gartland, C. M. Leu, S. Zhang, R. S. Davis, and
M. D. Cooper. 2005. Expression of the immunoregulatory molecule FcRH4
defines a distinctive tissue-based population of memory B cells. J. Exp. Med. 202:
783–791.
98. Weiss, G. E., E. H. Clark, S. Li, B. Traore, K. Kayentao, A. Ongoiba, J. N. Hernandez,
O. K. Doumbo, S. K. Pierce, O. H. Branch, and P. D. Crompton. 2011. A positive
correlation between atypical memory B cells and Plasmodium falciparum trans-
mission intensity in cross-sectional studies in Peru and Mali. PLoS ONE 6:
e15983.
99. Portugal, S., D. Doumtabe, B. Traore, L. H. Miller, M. Troye-Blomberg,
O. K. Doumbo, A. Dolo, S. K. Pierce, and P. D. Crompton. 2012. B cell analysis of
ethnic groups in Mali with differential susceptibility to malaria. Malar. J. 11: 162.
100. Illingworth, J., N. S. Butler, S. Roetynck, J. Mwacharo, S. K. Pierce, P. Bejon,
P. D. Crompton, K. Marsh, and F. M. Ndungu. 2013. Chronic exposure to
Plasmodium falciparum is associated with phenotypic evidence of B and T cell
exhaustion. J. Immunol. 190: 1038–1047
101. Muellenbeck, M. F., B. Ueberheide, B. Amulic, A. Epp, D. Fenyo, C. E. Busse,
M. Esen, M. Theisen, B. Mordmu¨ller, and H. Wardemann. 2013. Atypical and
classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J.
Exp. Med. PubMed DOI: 10.1084/jem.20121970
102. Bushell, K. M., C. So¨llner, B. Schuster-Boeckler, A. Bateman, and G. J. Wright.
2008. Large-scale screening for novel low-affinity extracellular protein interactions.
Genome Res. 18: 622–630.
103. Waisberg, M., G. C. Cerqueira, S. B. Yager, I. M. Francischetti, J. Lu, N. Gera,
P. Srinivasan, K. Miura, B. Rada, J. Lukszo, et al. 2012. Plasmodium falciparum
merozoite surface protein 1 blocks the proinflammatory protein S100P. Proc. Natl.
Acad. Sci. USA 109: 5429–5434.
104. Rogers, N. J., B. S. Hall, J. Obiero, G. A. Targett, and C. J. Sutherland. 2000. A
model for sequestration of the transmission stages of Plasmodium falciparum: ad-
hesion of gametocyte-infected erythrocytes to human bone marrow cells. Infect.
Immun. 68: 3455–3462.
105. Manicassamy, S., and B. Pulendran. 2009. Modulation of adaptive immunity with
Toll-like receptors. Semin. Immunol. 21: 185–193.
106. Boutlis, C. S., T. W. Yeo, and N. M. Anstey. 2006. Malaria tolerance: for whom
the cell tolls? Trends Parasitol. 22: 371–377.
107. Shio, M. T., S. C. Eisenbarth, M. Savaria, A. F. Vinet, M. J. Bellemare,
K. W. Harder, F. S. Sutterwala, D. S. Bohle, A. Descoteaux, R. A. Flavell, and
M. Olivier. 2009. Malarial hemozoin activates the NLRP3 inflammasome through
Lyn and Syk kinases. PLoS Pathog. 5: e1000559.
108. Krishnegowda, G., A. M. Hajjar, J. Zhu, E. J. Douglass, S. Uematsu, S. Akira,
A. S. Woods, and D. C. Gowda. 2005. Induction of proinflammatory responses in
macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell
signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and
regulation of GPI activity. J. Biol. Chem. 280: 8606–8616.
109. Parroche, P., F. N. Lauw, N. Goutagny, E. Latz, B. G. Monks, A. Visintin,
K. A. Halmen, M. Lamphier, M. Olivier, D. C. Bartholomeu, et al. 2007. Malaria
hemozoin is immunologically inert but radically enhances innate responses by presenting
malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci. USA 104: 1919–1924.
110. Sharma, S., R. B. DeOliveira, P. Kalantari, P. Parroche, N. Goutagny, Z. Jiang,
J. Chan, D. C. Bartholomeu, F. Lauw, J. P. Hall, et al. 2011. Innate immune
recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum
genome. Immunity 35: 194–207.
111. Crompton, P. D., M. Mircetic, G. Weiss, A. Baughman, C. Y. Huang, D. J. Topham,
J. J. Treanor, I. Sanz, F. E. Lee, A. P. Durbin, et al. 2009. The TLR9 ligand CpG
promotes the acquisition of Plasmodium falciparum-specific memory B cells in
malaria-naive individuals. J. Immunol. 182: 3318–3326.
112. Wrammert, J., D. Koutsonanos, G. M. Li, S. Edupuganti, J. Sui, M. Morrissey,
M. McCausland, I. Skountzou, M. Hornig, W. I. Lipkin, et al. 2011. Broadly
cross-reactive antibodies dominate the human B cell response against pandemic
H1N1 influenza virus infection. J. Exp. Med. 208: 181–193.
3046 BRIEF REVIEWS: B CELL RESPONSE TO MALARIA
 at M
ax-Planck Inst fuer Infektionsbiologie on June 30, 2020
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
